康臣藥業(01681.HK)：上半年腎科產品穩中有增，探索電商和新零售等機會
格隆匯 8 月 24日丨康臣藥業(01681.HK)公佈中期業績，截至2020年6月30日止6個月，公司收入為人民幣7.66億元%；公司權益股東應占溢利為人民幣2.09億元。每股基本盈利為人民幣0.2527元，擬派中期息每股0.08港元。
集團於截至2020年6月30日止六個月的收入為人民幣7.66億元。按產品系列分類，腎科系列產品銷售較去年錄得增長約4.9%，其中尿毒清顆粒仍然是集團的皇牌產品，維持在腎病口服現代中成藥市場的領先地位；醫用成像對比劑銷售雖然較去年減少約24.9%，仍然穩佔國內磁共振成像對比劑市場的前列；骨傷系列產品銷售下降約45.6%；皮膚系列產品銷售下降約79.2%；婦幼系列產品銷售減少約15.6%；及其他藥物銷售減少約59.7%。整體銷售收入的減少主要是由於期內受新冠肺炎疫情影響，醫用成像對比劑、婦幼系列產品及玉林製藥分部的銷售收入下跌所致。
於2020年上半年，集團的毛利為人民幣5.72億元。於2020年上半年，集團的平均毛利率為74.6%，與2019年同期的73.0%相比，增加1.6%，主要是由於期內產品銷售結構變化所致。
公告稱，於2020年上半年，集團的經營活動淨現金流入為人民幣3.24億元，相比2019年同期的人民幣1.40億元增加約131.5%，主要是由於期內加大貿易應收賬款催收力度所致。於2020年6月30日，集團的現金及銀行結餘為人民幣15.21億元，相比2019年12月31日的餘額人民幣13.83億元增加約10.0%。
在這個複雜多變、外部環境日益惡化的時代，管理層首要的任務是掌好舵，把握好康臣的發展方向，讓康臣旗艦行駛得更穩。通過落實"精耕、精煉、精神"三精的要求，以"逆週期擴張思維"，把握住彼退我進中的錯位機會，包括探索電商和新零售等機會，在"六保、一穩"上下功夫，達到凝心聚力，提速前進的核心目的：
1)確保能把握隨時可能出現的業務分拆機會；2)確保影像診斷業務快速發展；3)確保腎科藥物維持在腎病口服現代中成藥的領先；4)確保玉林製藥變革方案的成功落實；5)確保研發創新力量的不斷壯大，務求以腎病藥物為主的"1+6"方面新產品源源不斷注入；6)確保集團穩定而充足的現金流，而一穩就是實現集團穩定持續的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
